178 related articles for article (PubMed ID: 24870838)
21. Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.
Shay G; Tauro M; Loiodice F; Tortorella P; Sullivan DM; Hazlehurst LA; Lynch CC
Oncotarget; 2017 Jun; 8(26):41827-41840. PubMed ID: 28611279
[TBL] [Abstract][Full Text] [Related]
22. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
23. Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.
Teramachi J; Miki H; Nakamura S; Hiasa M; Harada T; Abe M
J Bone Miner Metab; 2023 May; 41(3):388-403. PubMed ID: 36856824
[TBL] [Abstract][Full Text] [Related]
24. [Development of the therapies targeting the interaction of myeloma cells with its bone marrow microenvironment].
Abe M
Rinsho Ketsueki; 2013 Jun; 54(6):522-32. PubMed ID: 23823090
[No Abstract] [Full Text] [Related]
25. [Implication of bone marrow microenvironment in pathogenesis of multiple myeloma].
Fišerová B; Kubiczková L; Sevčíková S; Hájek R
Klin Onkol; 2012; 25(4):234-40. PubMed ID: 22920162
[TBL] [Abstract][Full Text] [Related]
26. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
27. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
28. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
29. Do human myeloma cells directly produce the receptor activator of nuclear factor kappaB ligand (RANKL) or induce RANKL in the bone marrow microenvironment?
Giuliani N; Colla S; Rizzoli V; Barillé-Nion S; Bataille R
Cancer Res; 2004 Jan; 64(2):772-3; author reply 774-5. PubMed ID: 14744797
[No Abstract] [Full Text] [Related]
30. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma.
Ehrlich LA; Roodman GD
Immunol Rev; 2005 Dec; 208():252-66. PubMed ID: 16313353
[TBL] [Abstract][Full Text] [Related]
31. Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.
Takeuchi K; Abe M; Hiasa M; Oda A; Amou H; Kido S; Harada T; Tanaka O; Miki H; Nakamura S; Nakano A; Kagawa K; Yata K; Ozaki S; Matsumoto T
PLoS One; 2010 Mar; 5(3):e9870. PubMed ID: 20360846
[TBL] [Abstract][Full Text] [Related]
32. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma.
Manier S; Kawano Y; Bianchi G; Roccaro AM; Ghobrial IM
Curr Opin Hematol; 2016 Jul; 23(4):426-33. PubMed ID: 27101529
[TBL] [Abstract][Full Text] [Related]
33. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
35. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
36. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
37. A role of TRAIL in killing osteoblasts by myeloma cells.
Tinhofer I; Biedermann R; Krismer M; Crazzolara R; Greil R
FASEB J; 2006 Apr; 20(6):759-61. PubMed ID: 16436464
[TBL] [Abstract][Full Text] [Related]
38. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.
Yata K; Yaccoby S
Leukemia; 2004 Nov; 18(11):1891-7. PubMed ID: 15385929
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Corso A; Ferretti E; Lazzarino M
Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
[TBL] [Abstract][Full Text] [Related]
40. In vitro growth of human multiple myeloma: implications for biology and therapy.
Caligaris-Cappio F; Gregoretti MG; Ghia P; Bergui L
Hematol Oncol Clin North Am; 1992 Apr; 6(2):257-71. PubMed ID: 1582973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
